EMA Authorised: Ibrance (Palbociclib) — Pfizer Europe MA EEIG

View source ↗

Summary

The EMA authorised palbociclib (Ibrance) for breast cancer under Pfizer Europe MA EEIG. The decision date is 06 March 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• IBRANCE (PALBOCICLIB)

Snippet

Status: Authorised. Therapeutic area: Breast Neoplasms. MAH: Pfizer Europe MA EEIG. Decision date: 06/03/2025